Literature DB >> 21990027

The genetics of antipsychotic induced tremors: a genome-wide pathway analysis on the STEP-BD SCP sample.

Antonio Drago1, Concetta Crisafulli, Alessandro Serretti.   

Abstract

Extrapyramidal symptoms (EPS) are associated with antipsychotic treatment. The exact definition of the genetic variants that influence the antipsychotic induced EPS would dramatically increase the quality of antipsychotic prescriptions. We investigated this issue in a subsample of the Systematic Treatment Enhancement Program for Bipolar Disorder (STEP-BD). Four hundred nine manic patients were treated with antipsychotics and had complete clinical and genetic data. Outcome was an item of the Clinical Monitoring Form which scored tremors from 0 to 4 at each clinical visit. Visits were scheduled according to clinical issues, based on a naturalistic approach. A genomic inflation factor of 1.017 resulted after genetic quality control. Single SNPs GWAS (Plink) and molecular pathway GWAS were conducted (SNP ratio test, KEGG depository). No single SNP reached GWAS significance level of association. Molecular pathways related to cell survival events and lipid synthesis were significantly associated with antipsychotic induced EPS (P = 0.0009 for Hsa04512, Hsa01031, Hsa00230, Hsa04510, Hsa03320, Hsa04930, and Hsa04115; P = 0.0019 for Hsa04020 and Hsa00561). This finding was consistent with previous GWAS studies.
Copyright © 2011 Wiley Periodicals, Inc.

Entities:  

Mesh:

Substances:

Year:  2011        PMID: 21990027     DOI: 10.1002/ajmg.b.31245

Source DB:  PubMed          Journal:  Am J Med Genet B Neuropsychiatr Genet        ISSN: 1552-4841            Impact factor:   3.568


  7 in total

1.  Pharmacogenetic study of antipsychotic induced acute extrapyramidal symptoms in a first episode psychosis cohort: role of dopamine, serotonin and glutamate candidate genes.

Authors:  S Mas; P Gassó; A Lafuente; M Bioque; A Lobo; A Gonzàlez-Pinto; M S Olmeda; I Corripio; A Llerena; B Cabrera; J Saiz-Ruiz; M Bernardo
Journal:  Pharmacogenomics J       Date:  2016-06-07       Impact factor: 3.550

2.  Genetics of psychotropic medication induced side effects in two independent samples of bipolar patients.

Authors:  Chiara Fabbri; Daniel Souery; Raffaella Calati; Concetta Crisafulli; Armando Chierchia; Diego Albani; Gianluigi Forloni; Alberto Chiesa; Rosalba Martines; Othman Sentissi; Julien Mendlewicz; Giovanni De Girolamo; Alessandro Serretti
Journal:  J Neural Transm (Vienna)       Date:  2014-08-17       Impact factor: 3.575

Review 3.  Relating human genetic variation to variation in drug responses.

Authors:  Ashraf G Madian; Heather E Wheeler; Richard Baker Jones; M Eileen Dolan
Journal:  Trends Genet       Date:  2012-07-26       Impact factor: 11.639

Review 4.  From pharmacogenetics to pharmacogenomics: the way toward the personalization of antidepressant treatment.

Authors:  Chiara Fabbri; Stefano Porcelli; Alessandro Serretti
Journal:  Can J Psychiatry       Date:  2014-02       Impact factor: 4.356

5.  Detecting key genes regulated by miRNAs in dysfunctional crosstalk pathway of myasthenia gravis.

Authors:  Yuze Cao; Jianjian Wang; Huixue Zhang; Qinghua Tian; Lixia Chen; Shangwei Ning; Peifang Liu; Xuesong Sun; Xiaoyu Lu; Chang Song; Shuai Zhang; Bo Xiao; Lihua Wang
Journal:  Biomed Res Int       Date:  2015-02-01       Impact factor: 3.411

Review 6.  Review of Cohort Studies for Mood Disorders.

Authors:  Hong Jin Jeon; Ji Hyun Baek; Yong-Min Ahn; Se Joo Kim; Tae Hyun Ha; Boseok Cha; Eunsoo Moon; Hee-Ju Kang; Vin Ryu; Chul-Hyun Cho; Jung-Yoon Heo; Kiwon Kim; Heon-Jeong Lee
Journal:  Psychiatry Investig       Date:  2016-05-18       Impact factor: 2.505

7.  Pathway analysis using information from allele-specific gene methylation in genome-wide association studies for bipolar disorder.

Authors:  Li-Chung Chuang; Chung-Feng Kao; Wei-Liang Shih; Po-Hsiu Kuo
Journal:  PLoS One       Date:  2013-01-09       Impact factor: 3.240

  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.